Kolexia
Clavelou Pierre
Neurologie
Hôpital Gabriel Montpied
Clermont-Ferrand, France
279 Activités
2 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Sclérose en plaques Sclérose Sclérose en plaques récurrente-rémittente Sclérose en plaques chronique progressive COVID-19 Sclérose latérale amyotrophique Maladies démyélinisantes Maladies du motoneurone Leucoencéphalopathie multifocale progressive

Industries

Sanofi
30 collaboration(s)
Dernière en 2023
Janssen
30 collaboration(s)
Dernière en 2023
Novartis
22 collaboration(s)
Dernière en 2023
Merck-Serono
20 collaboration(s)
Dernière en 2023

Dernières activités

A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis: An Adaptive Phase 2a/2b, Randomized, Double-Blind, Parallel-Group Study to Investigate the Safety and Efficacy of LY3541860 Compared to Placebo in Slowing the Occurrence of New T1 Gadolinium-Enhancing Lesions in Adult Participants With Relapsing Multiple Sclerosis
Essai Clinique (Lilly)   19 mars 2024
Réforme du troisième cycle des études médicales en France
La Presse Médicale Formation   12 février 2024
Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis.
JAMA neurology   12 février 2024
TELECOG-MS: Multicentre Randomized Blinded Controlled Study of Specific Telerehabilitation of Multidomain Cognitive Impairment in Multiple Sclerosis Using Mixed Evaluation and Ecological Validity
Essai Clinique (Celgene)   06 février 2024
RESPONSE: French Registry for Monitoring Pregnancies and Children of Women With Multiple Sclerosis Within The Observatoire Français de la Sclérose en Plaque (OFSEP) Cohort
Essai Clinique (Hospices Civils de Lyon)   25 janvier 2024
COVID-19 outcomes in patients with multiple sclerosis: Understanding changes from 2020 to 2022.
Multiple sclerosis (Houndmills, Basingstoke, England)   21 janvier 2024
Correction: Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis.
Neurology and therapy   20 novembre 2023
STOP-I-SEP: Disease Modifying Therapies Withdrawal in Inactive Secondary Progressive Multiple Sclerosis Patients Older Than 50 Years
Essai Clinique (CHU Rennes)   23 octobre 2023
Comparison of Two Methods for Estimating MS-Related Mortality: The Excess Mortality vs. the Cause-Specific Frameworks.
Neurology   12 octobre 2023
Teriflunomide and Time to Clinical Multiple Sclerosis in Patients With Radiologically Isolated Syndrome: The TERIS Randomized Clinical Trial.
JAMA neurology   10 octobre 2023